Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • ${value}

Filter Results (22${count})

  • Therapeutic Pipeline Program, 2016
    Cognitive Behavioral Therapy for Anxiety Disorders in Parkinson's Disease

    Study Rationale:
    Anxiety disorders occur in up to 35 percent of people with Parkinson's disease and can have a negative impact on gait, involuntary movements, motor fluctuations and quality of life...

  • MJFF Research Grant, 2009
    The Validation of Anxiety Scales in Parkinson's Disease

    This study has two objectives:
    1. To assess the occurrence and symptoms of anxiety disorders in Parkinson's disease, including atypical anxiety syndromes, and anxiety states...

  • MJFF Research Grant, 2011
    Assessing and Diagnosing Anxiety in Patients with Parkinson's Disease

    Promising Outcomes of Original Grant:
    A previous MJFF sponsored study showed that the available anxiety questionnaires are not suitable to assess anxiety in Parkinson’s disease (PD). The different...

  • Therapeutic Pipeline Program, 2015
    The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson’s Disease

    Study Rationale:                             
    Anxiety is a common non-motor symptom among individuals with Parkinson’s disease (PD) and is associated with a reduced quality of life. Despite this...

  • Research Grant, 2020
    Identification of Therapeutic Circuits to Address Anxiety and Depression Symptoms in Parkinson’s Disease

    Study Rationale: Parkinson’s disease patients often experience depression and anxiety. Addressing these non-motor symptoms has not been the focus of Parkinson’s disease research though psychiatric...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022
    Assessment of Alpha-synuclein Aggregation Inhibitor ASN121151 as a Potential New Treatment for Parkinson’s Disease

    Study Rationale: Genetic defects in the gene encoding alpha-synuclein cause the protein to aggregate in the brains of people with a familial form of Parkinson’s disease (PD). We have developed a novel...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.